30
Participants
Start Date
September 19, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
September 30, 2027
Peptide vaccine IPX
"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
NOT_YET_RECRUITING
Pediatrics III, West German Cancer Centre, University Hospital, Essen
NOT_YET_RECRUITING
Universitätsklinikum, Klinik für Kinder- und Jugendmedizin, Frankfurt am Main
RECRUITING
University Children's Hostpital, Tübingen
NOT_YET_RECRUITING
Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum, Freiburg im Breisgau
Deutsches Konsortium fürTranslationale Krebsforschung (DKTK)
UNKNOWN
Cooperative Ewing Sarkom Studiengruppe
UNKNOWN
Cooperative Weichteilsarkom Study Group
OTHER
University Hospital Tuebingen
OTHER